# Novartis to acquire Mariana Oncology for up to $1.75 billion

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments. Mariana Oncology develops radiopharmaceuticals for cancer treatment, including lead program MC-339 for small cell lung cancer.

- Type: Acquisition
- Announced: 2024-05-02
- Where: Watertown, Massachusetts, United States
- Value: $1.00B
- Status: announced
- Products: radiopharmaceuticals, radioligand therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md) (acquirer)
- [Mariana Oncology](https://endata.com/companies/77178.md) (target)

## Sources

- [marianaoncology.com](https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/), 2024-05-02: "Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.